Developer docs
API playgroundTry for free, no card

Search company profiles

RocketVax

Full company profile

uuid0003fwn

Namestring
RocketVax
Legal namestring
RocketVax AG
Websiteurl
rocketvax.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

RocketVax AG is a privately held Swiss biotechnology company, headquartered in Basel and operating as a subsidiary of Swiss Rockets AG. The company develops next-generation vaccines based on proprietary live-attenuated virus technology, with a primary focus on SARS-CoV-2 and a stated platform ambition to address additional infectious disease targets. Its two lead candidates, RVX-sCPD9 and RVX-OTS (OTS-228), are intranasal live-attenuated vaccine candidates designed to induce both mucosal and systemic immunity, with the aim of preventing both infection and transmission of current and emerging COVID-19 variants.

The underlying technology platform, branded VIRUFLEX, integrates reverse genetic engineering, genome recoding (One-to-Stop / OTS mutations), and Single-Cycle Virus approaches to engineer safe, highly attenuated vaccine candidates. Preclinical data published in Cell Reports, Nature Microbiology, Molecular Therapy, Nature Communications, and npj Vaccines demonstrate safety, efficacy (approximately 3x higher than comparators in animal models), and genomic stability, including prevention of virus transmission in hamster models. Development is supported by collaborations with the University of Bern, University of Basel, Freie Universität Berlin, and Friedrich-Loeffler-Institut, with GMP manufacturing provided by CDMO HALIX B.V. and U.S. clinical and commercial advancement anchored by NIH/NIAID Project NextGen sponsorship and a strategic partnership with Emergent BioSolutions.

The business model is pre-commercial: RocketVax expects to generate revenue through vaccine licensing and royalties, strategic partnership milestone payments, and non-dilutive grant funding. Go-to-market is executed via co-development with academic institutions, CDMO manufacturing partnerships, and pharmaceutical strategic alliances (notably Emergent BioSolutions for U.S. manufacturing and commercialization of four pipeline candidates). The company is participating in the SIX Swiss Exchange Sparks IPO Academy, indicating intent toward public-market readiness, though no public listing has occurred.

Short descriptiontext

RocketVax AG is a Swiss biotech subsidiary of Swiss Rockets AG developing next-generation intranasal live-attenuated COVID-19 vaccines (RVX-sCPD9 and RVX-OTS) using proprietary VIRUFLEX genome-recoding platform, partnered with NIH/NIAID, HALIX, and Emergent BioSolutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live-attenuated vaccines, next-generation vaccines, intranasal vaccine delivery, viral reverse genetics, pandemic preparedness platform
Industry4 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Licensing and Royalties
TypeLicensing Royalties
Description

Pre-revenue biotech company developing next-generation live-attenuated vaccines. Expected to generate revenue through licensing vaccine technology and receiving royalties from commercialized products upon successful clinical development and regulatory approval.

rocketvax.com
2Strategic Partnership Payments
TypeLicensing Royalties
Description

Revenue expected from strategic partnerships including upfront payments, milestone payments, and commercialization royalties from partners like Emergent BioSolutions who will lead U.S. manufacturing and commercialization.

rocketvax.com
3Non-Dilutive Funding
TypeManaged Services
Description

Non-dilutive financial support from government sources including NIH/NIAID Project NextGen for clinical trial sponsorship, providing funding without equity dilution.

rocketvax.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1VIRUFLEX
Description

State-of-the-art endemic readiness platform designed to accelerate development and deployment of next-generation vaccines in response to future pandemics

rocketvax.com
+1 more record
Core offering1 text field

RocketVax AG develops next-generation live-attenuated virus vaccines against SARS-CoV-2 and other infectious diseases, using proprietary reverse genetic engineering and genome recoding technology delivered via the VIRUFLEX™ platform. Its lead candidates RVX-sCPD9 and RVX-OTS (OTS-228) are needle-free intranasal spray vaccines designed to provide mucosal immunity, broader variant protection, and transmission blocking for current and emergent COVID-19 variants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 3x higher efficacy in animal studies compared to conventional vaccine approaches
+6 more records
Product overview1 text field

Rocketvax AG is a Swiss biotech company developing next-generation vaccines based on live-attenuated virus technology. The company's core offerings include two lead vaccine candidates: RVX-sCPD9 and RVX-OTS (OTS-228), both live-attenuated SARS-CoV-2 vaccines administered via nasal spray. These vaccines leverage the proprietary VIRUFLEX™ platform which uses reverse genetic engineering technology. The platform enables rapid development of vaccines that offer broad protection against current and emergent SARS-CoV-2 variants through comprehensive immune activation including mucosal immunity at the respiratory tract entry point. All current products are in preclinical development stage with Phase 1 clinical trials in preparation.

Product and service3 records
1RVX-sCPD9
CategoryLive-attenuated intranasal COVID-19 vaccine
Description

Lead live-attenuated SARS-CoV-2 vaccine candidate administered via nasal spray, demonstrated to elicit superior mucosal and systemic immunity to SARS-CoV-2 variants in preclinical studies; selected for the NIH/NIAID Project NextGen Phase 1 clinical trial.

2RVX-OTS (OTS-228)
CategoryLive-attenuated intranasal COVID-19 vaccine
Description

One-to-Stop (OTS) mutations SARS-CoV-2 live-attenuated vaccine candidate using a proprietary OTS genetic strategy for virus attenuation; demonstrated excellent safety, efficacy, genomic stability and transmission-blocking immunity against Omicron BA.2, BA.5 and XBB.1.5 in preclinical models.

3VIRUFLEX™ Platform
CategoryVaccine development technology platform
Description

Proprietary endemic readiness vaccine development platform integrating reverse genetic engineering, scalable production processes and global partnerships to accelerate development and deployment of next-generation vaccines for current and future pandemics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-12
Description

Strategic investment and partnership for U.S. manufacturing and commercialization of four pipeline candidates (infectious diseases, cancer, autoimmune disorders). Emergent to leverage manufacturing infrastructure and regulatory expertise. Rocketvax receives investment support for research and infrastructure development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-16
Description

Strategic CDMO partnership for VIRUFLEX™ platform. HALIX provides GMP-grade manufacturing, expertise in viral vector manufacturing, and scalable infrastructure for rapid vaccine production scale-up. Collaboration focuses on pandemic readiness and next-generation nasal COVID-19 vaccine development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

Project NextGen collaboration where NIAID will support Phase 1 clinical study with Rocketvax's RVX-sCPD9 live-attenuated nasal vaccine candidate, subject to regulatory approval. NIH provides non-dilutive financial support for clinical advancement.

4SIX Swiss Exchange
Strategic tierMinorTypeOthersAnnounced on2023-10-30
Description

Selected participant in Sparks IPO Academy, a six-month structured program for IPO preparation providing access to capital markets specialists, networking with CFOs of listed companies, and engagement with potential investors.

rocketvax.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific collaboration led by Professor Dr. Volker Thiel (Chief Scientist of Rocketvax and Professor of Virology at University of Bern) for development of live-attenuated SARS-CoV-2 vaccine candidates including OTS-228.

6Friedrich-Loeffler-Institut (FLI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Germany's Federal Research Institute for Animal Health conducted preclinical studies demonstrating OTS-228 vaccine efficacy, safety, and genomic stability in Syrian hamster models under direction of Professor Dr. Martin Beer, Director of Institute of Diagnostic Virology.

rocketvax.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research collaboration comparing efficacy of live-attenuated vaccine sCPD9-ΔFCS with mRNA vaccine BNT162b2 in preventing SARS-CoV-2 transmission. Research team led by Dr. Jakob Trimpert demonstrated superior performance of intranasal live-attenuated vaccine.

Strategic tierSupportingTypeOthers
Description

Swiss National Research Program 'COVID-19' (NRP 78) providing financial support for live-attenuated coronavirus vaccine research and development collaboration.

9German Research Foundation (DFG)
Strategic tierSupportingTypeOthers
Description

German Research Foundation project 'Recoding the SARS-CoV-2 Genome - A Multidisciplinary Approach to Generate Live-Attenuated Coronavirus Vaccines' providing funding for vaccine development research.

rocketvax.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Professor Thomas Klimkait's team for development of single-cycle virus vaccine approach. University Hospital of Basel and Swiss Tropical and Public Health Institute also part of research partnership. Supported by InnoSuisse grant.

Strategic tierCoreTypeOthers
Description

Rocketvax AG is a subsidiary of Swiss Rockets AG, a Swiss biotech incubator and accelerator supporting growth of companies with focus on oncology and vaccine development. Rocketvax is part of the Swiss Rockets group of companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing live-attenuated vaccines including TNX-1800 (horsepox-based COVID-19 vaccine) and TNX-801 (smallpox vaccine). Comparable live-attenuated platform approach to RocketVax's technology.

TypeDirect peer
Description

Clinical-stage biotech developing live-attenuated vaccines using codon deoptimization and synthetic biology. Most direct peer to RocketVax given shared live-attenuated virus technology focus and intranasal delivery approach for respiratory viruses.

TypeDirect peer
Description

Approved COVID-19 vaccine developer using protein subunit technology. Direct competitor in the prophylactic human COVID-19 vaccine market that RocketVax targets with its next-generation approach.

TypeEmerging player
Description

Developer of intranasal parainfluenza virus vector-based vaccines including COVID-19 candidates. Comparable intranasal vaccine delivery approach targeting mucosal immunity, though uses viral vector rather than live-attenuated.

TypeBroad incumbent
Description

Global pharmaceutical leader with BioNTech-partnered COVID-19 vaccine Comirnaty. Dominant incumbent in the COVID-19 vaccine market that RocketVax targets, with massive manufacturing and commercial scale advantages.

TypeBroad incumbent
Description

mRNA vaccine leader with approved COVID-19 vaccine and broad pipeline. Directly competes in the next-generation COVID-19 vaccine market that RocketVax targets, though Moderna uses mRNA technology rather than live-attenuated.

TypeBroad incumbent
Description

Global pharmaceutical company with COVID-19 vaccine (Vaxzevria) and broad infectious disease vaccine portfolio. Large incumbent operating in the same respiratory virus vaccine market with established global commercialization capabilities.

TypeDirect peer
Description

Developer of intranasal live-attenuated vaccines for respiratory viruses including RSV and COVID-19. Direct competitor using similar intranasal live-attenuated platform targeting the same mucosal immunity differentiation.

TypeBroad incumbent
Description

mRNA vaccine pioneer with Pfizer-partnered COVID-19 vaccine and expanding pipeline. Competes in the broader next-generation COVID-19 vaccine market and is developing intranasal candidates that could challenge RocketVax's mucosal immunity advantage.

TypeBroad incumbent
Description

Public biotech specializing in vaccines and therapeutics with established manufacturing infrastructure. Strategic partner to RocketVax for U.S. commercialization, while also operating its own vaccine pipeline including COVID-19 candidates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RocketVax

Biotechnology Vaccinesrocketvax.com

RocketVax AG is a Swiss biotech subsidiary of Swiss Rockets AG developing next-generation intranasal live-attenuated COVID-19 vaccines (RVX-sCPD9 and RVX-OTS) using proprietary VIRUFLEX genome-recoding platform, partnered with NIH/NIAID, HALIX, and Emergent BioSolutions.

What RocketVax does

RocketVax AG is a privately held Swiss biotechnology company, headquartered in Basel and operating as a subsidiary of Swiss Rockets AG. The company develops next-generation vaccines based on proprietary live-attenuated virus technology, with a primary focus on SARS-CoV-2 and a stated platform ambition to address additional infectious disease targets. Its two lead candidates, RVX-sCPD9 and RVX-OTS (OTS-228), are intranasal live-attenuated vaccine candidates designed to induce both mucosal and systemic immunity, with the aim of preventing both infection and transmission of current and emerging COVID-19 variants.

The underlying technology platform, branded VIRUFLEX, integrates reverse genetic engineering, genome recoding (One-to-Stop / OTS mutations), and Single-Cycle Virus approaches to engineer safe, highly attenuated vaccine candidates. Preclinical data published in Cell Reports, Nature Microbiology, Molecular Therapy, Nature Communications, and npj Vaccines demonstrate safety, efficacy (approximately 3x higher than comparators in animal models), and genomic stability, including prevention of virus transmission in hamster models. Development is supported by collaborations with the University of Bern, University of Basel, Freie Universität Berlin, and Friedrich-Loeffler-Institut, with GMP manufacturing provided by CDMO HALIX B.V. and U.S. clinical and commercial advancement anchored by NIH/NIAID Project NextGen sponsorship and a strategic partnership with Emergent BioSolutions.

The business model is pre-commercial: RocketVax expects to generate revenue through vaccine licensing and royalties, strategic partnership milestone payments, and non-dilutive grant funding. Go-to-market is executed via co-development with academic institutions, CDMO manufacturing partnerships, and pharmaceutical strategic alliances (notably Emergent BioSolutions for U.S. manufacturing and commercialization of four pipeline candidates). The company is participating in the SIX Swiss Exchange Sparks IPO Academy, indicating intent toward public-market readiness, though no public listing has occurred.

RocketVax firmographics

Firmographics
Name
RocketVax
Legal name
RocketVax AG
Website
https://rocketvax.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
RocketVax AG is a Swiss biotech subsidiary of Swiss Rockets AG developing next-generation intranasal live-attenuated COVID-19 vaccines (RVX-sCPD9 and RVX-OTS) using proprietary VIRUFLEX genome-recoding platform, partnered with NIH/NIAID, HALIX, and Emergent BioSolutions.
Ownership category
akta.pro rank

RocketVax industry classification

Industry
Product category
Biotechnology Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines

Keywords

  • Live-attenuated vaccines
  • Next-generation vaccines
  • Intranasal vaccine delivery
  • Viral reverse genetics
  • Pandemic preparedness platform

Where RocketVax is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

RocketVax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Vaccine Licensing and Royalties: Pre-revenue biotech company developing next-generation live-attenuated vaccines. Expected to generate revenue through licensing vaccine technology and receiving royalties from commercialized products upon successful clinical development and regulatory approval.
  2. Strategic Partnership Payments: Revenue expected from strategic partnerships including upfront payments, milestone payments, and commercialization royalties from partners like Emergent BioSolutions who will lead U.S. manufacturing and commercialization.
  3. Non-Dilutive Funding: Non-dilutive financial support from government sources including NIH/NIAID Project NextGen for clinical trial sponsorship, providing funding without equity dilution.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

RocketVax product offering

Product offering

Core offering

RocketVax AG develops next-generation live-attenuated virus vaccines against SARS-CoV-2 and other infectious diseases, using proprietary reverse genetic engineering and genome recoding technology delivered via the VIRUFLEX™ platform. Its lead candidates RVX-sCPD9 and RVX-OTS (OTS-228) are needle-free intranasal spray vaccines designed to provide mucosal immunity, broader variant protection, and transmission blocking for current and emergent COVID-19 variants.

Product overview

Rocketvax AG is a Swiss biotech company developing next-generation vaccines based on live-attenuated virus technology. The company's core offerings include two lead vaccine candidates: RVX-sCPD9 and RVX-OTS (OTS-228), both live-attenuated SARS-CoV-2 vaccines administered via nasal spray. These vaccines leverage the proprietary VIRUFLEX™ platform which uses reverse genetic engineering technology. The platform enables rapid development of vaccines that offer broad protection against current and emergent SARS-CoV-2 variants through comprehensive immune activation including mucosal immunity at the respiratory tract entry point. All current products are in preclinical development stage with Phase 1 clinical trials in preparation.

Differentiator

Problem solved

Functional benefit

Brands

  • VIRUFLEX: State-of-the-art endemic readiness platform designed to accelerate development and deployment of next-generation vaccines in response to future pandemics
  • Viruflex

Products and services

  • RVX-sCPD9 Lead live-attenuated SARS-CoV-2 vaccine candidate administered via nasal spray, demonstrated to elicit superior mucosal and systemic immunity to SARS-CoV-2 variants in preclinical studies; selected for the NIH/NIAID Project NextGen Phase 1 clinical trial.
  • RVX-OTS (OTS-228) One-to-Stop (OTS) mutations SARS-CoV-2 live-attenuated vaccine candidate using a proprietary OTS genetic strategy for virus attenuation; demonstrated excellent safety, efficacy, genomic stability and transmission-blocking immunity against Omicron BA.2, BA.5 and XBB.1.5 in preclinical models.
  • VIRUFLEX™ Platform Proprietary endemic readiness vaccine development platform integrating reverse genetic engineering, scalable production processes and global partnerships to accelerate development and deployment of next-generation vaccines for current and future pandemics.

Quantifiable outcome

  • 3x higher efficacy in animal studies compared to conventional vaccine approaches
  • +6 more outcomes

Companies that use RocketVax

Customer profile

Segments3 records

Ideal customer profiles3 records

RocketVax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

RocketVax partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, minor and supporting.

  • Emergent BioSolutionscoreStrategic or Co-development Partner · 12 March 2025Strategic investment and partnership for U.S. manufacturing and commercialization of four pipeline candidates (infectious diseases, cancer, autoimmune disorders). Emergent to leverage manufacturing infrastructure and regulatory expertise. Rocketvax receives investment support for research and infrastructure development.
  • HALIX B.V.coreTechnology or Integration · 16 December 2024Strategic CDMO partnership for VIRUFLEX™ platform. HALIX provides GMP-grade manufacturing, expertise in viral vector manufacturing, and scalable infrastructure for rapid vaccine production scale-up. Collaboration focuses on pandemic readiness and next-generation nasal COVID-19 vaccine development.
  • National Institutes of Health (NIH)/NIAIDcoreStrategic or Co-development Partner · 13 June 2024Project NextGen collaboration where NIAID will support Phase 1 clinical study with Rocketvax's RVX-sCPD9 live-attenuated nasal vaccine candidate, subject to regulatory approval. NIH provides non-dilutive financial support for clinical advancement.
  • SIX Swiss ExchangeminorOthers · 30 October 2023Selected participant in Sparks IPO Academy, a six-month structured program for IPO preparation providing access to capital markets specialists, networking with CFOs of listed companies, and engagement with potential investors.
  • University of BerncoreStrategic or Co-development PartnerScientific collaboration led by Professor Dr. Volker Thiel (Chief Scientist of Rocketvax and Professor of Virology at University of Bern) for development of live-attenuated SARS-CoV-2 vaccine candidates including OTS-228.
  • Friedrich-Loeffler-Institut (FLI)coreStrategic or Co-development PartnerGermany's Federal Research Institute for Animal Health conducted preclinical studies demonstrating OTS-228 vaccine efficacy, safety, and genomic stability in Syrian hamster models under direction of Professor Dr. Martin Beer, Director of Institute of Diagnostic Virology.
  • Freie Universität BerlincoreStrategic or Co-development PartnerJoint research collaboration comparing efficacy of live-attenuated vaccine sCPD9-ΔFCS with mRNA vaccine BNT162b2 in preventing SARS-CoV-2 transmission. Research team led by Dr. Jakob Trimpert demonstrated superior performance of intranasal live-attenuated vaccine.
  • Swiss National Science Foundation (SNSF)supportingOthersSwiss National Research Program 'COVID-19' (NRP 78) providing financial support for live-attenuated coronavirus vaccine research and development collaboration.
  • German Research Foundation (DFG)supportingOthersGerman Research Foundation project 'Recoding the SARS-CoV-2 Genome - A Multidisciplinary Approach to Generate Live-Attenuated Coronavirus Vaccines' providing funding for vaccine development research.
  • University of BaselcoreStrategic or Co-development PartnerResearch collaboration with Professor Thomas Klimkait's team for development of single-cycle virus vaccine approach. University Hospital of Basel and Swiss Tropical and Public Health Institute also part of research partnership. Supported by InnoSuisse grant.
  • Swiss Rockets AG (Parent Company)coreOthersRocketvax AG is a subsidiary of Swiss Rockets AG, a Swiss biotech incubator and accelerator supporting growth of companies with focus on oncology and vaccine development. Rocketvax is part of the Swiss Rockets group of companies.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

RocketVax competitors and assessment

Company assessment

Direct peers

  • Tonix Pharmaceuticals: Clinical-stage biotech developing live-attenuated vaccines including TNX-1800 (horsepox-based COVID-19 vaccine) and TNX-801 (smallpox vaccine). Comparable live-attenuated platform approach to RocketVax's technology.
  • Codagenix: Clinical-stage biotech developing live-attenuated vaccines using codon deoptimization and synthetic biology. Most direct peer to RocketVax given shared live-attenuated virus technology focus and intranasal delivery approach for respiratory viruses.
  • Novavax: Approved COVID-19 vaccine developer using protein subunit technology. Direct competitor in the prophylactic human COVID-19 vaccine market that RocketVax targets with its next-generation approach.
  • Meissa Vaccines: Developer of intranasal live-attenuated vaccines for respiratory viruses including RSV and COVID-19. Direct competitor using similar intranasal live-attenuated platform targeting the same mucosal immunity differentiation.

Emerging players

  • Blue Lake Biotechnology: Developer of intranasal parainfluenza virus vector-based vaccines including COVID-19 candidates. Comparable intranasal vaccine delivery approach targeting mucosal immunity, though uses viral vector rather than live-attenuated.

Broad incumbents

  • Pfizer: Global pharmaceutical leader with BioNTech-partnered COVID-19 vaccine Comirnaty. Dominant incumbent in the COVID-19 vaccine market that RocketVax targets, with massive manufacturing and commercial scale advantages.
  • Moderna: mRNA vaccine leader with approved COVID-19 vaccine and broad pipeline. Directly competes in the next-generation COVID-19 vaccine market that RocketVax targets, though Moderna uses mRNA technology rather than live-attenuated.
  • AstraZeneca: Global pharmaceutical company with COVID-19 vaccine (Vaxzevria) and broad infectious disease vaccine portfolio. Large incumbent operating in the same respiratory virus vaccine market with established global commercialization capabilities.
  • BioNTech: mRNA vaccine pioneer with Pfizer-partnered COVID-19 vaccine and expanding pipeline. Competes in the broader next-generation COVID-19 vaccine market and is developing intranasal candidates that could challenge RocketVax's mucosal immunity advantage.
  • Emergent BioSolutions: Public biotech specializing in vaccines and therapeutics with established manufacturing infrastructure. Strategic partner to RocketVax for U.S. commercialization, while also operating its own vaccine pipeline including COVID-19 candidates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RocketVax social profiles

Digital presence

RocketVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RocketVax leadership team

Management profile

Number of profiles

Profiles20 records

RocketVax funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RocketVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RocketVax

What does RocketVax do?

RocketVax AG develops next-generation live-attenuated virus vaccines against SARS-CoV-2 and other infectious diseases, using proprietary reverse genetic engineering and genome recoding technology delivered via the VIRUFLEX™ platform. Its lead candidates RVX-sCPD9 and RVX-OTS (OTS-228) are needle-free intranasal spray vaccines designed to provide mucosal immunity, broader variant protection, and transmission blocking for current and emergent COVID-19 variants.

Is RocketVax a public or private company?

RocketVax is a private company. It is classified as venture growth investor backed and is currently operating.

When was RocketVax founded?

RocketVax was founded in 2018. It employs 1 to 10 people.

Where is RocketVax based?

RocketVax is headquartered in Basel, Switzerland, in the Europe region.

How does RocketVax make money?

Three revenue lines are on record. Vaccine Licensing and Royalties are the primary driver. The others are strategic Partnership Payments and non-Dilutive Funding.

Who are RocketVax's main competitors?

Direct peers on record are Tonix Pharmaceuticals, Codagenix, Novavax and Meissa Vaccines. Blue Lake Biotechnology is listed as an emerging player. Broad incumbents are Pfizer, Moderna, AstraZeneca, BioNTech and Emergent BioSolutions.

Does RocketVax have an API?

No public API is recorded for RocketVax.

What industry is RocketVax in?

RocketVax's product category is Biotechnology Vaccines. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceEmergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product CandidatesEmergent BioSolutions announced a strategic investment and partnership with Swiss biotech company Rocketvax Ltd, aimed at developing next-generation vaccines, including a nasal spray SARS-CoV-2 vaccine. This collaboration includes supporting Rocketvax's pipeline candidates and a clinical trial with the NIH, with Emergent potentially leading U.S. manufacturing and commercialization. The partnership is designed to accelerate vaccine development and broaden global healthcare innovation.startupticker.chRocketVax raises CHF 7.2 million to advance clinical studies for its COVID-19 vaccineBasel-based RocketVax has secured CHF 7.2 million in Seed A financing to fund the pre-clinical development and clinical trial preparation of its COVID-19 vaccine candidate, RVX-13. The funding, provided by institutional investors, private backers, and grants from Innosuisse, the Canton of Basel-Stadt, and University Hospital Basel, will support animal studies and GMP scale-up production for Phase 1 and 2 trials. These upcoming clinical trials will be conducted in collaboration with Batavia Biosciences in the Netherlands.RocketvaxRocketVax successfully raises CHF 7.2 million of seed fundingRocketVax AG has secured CHF 7.2 million in Seed A financing to fund the pre-clinical development of its Covid-19 vaccine, RVX-13. The funding was provided by InnoSuisse, the Canton of Basel-Stadt, the University Hospital Basel, and private investors, with proceeds allocated for animal model studies and GMP scale-up production. RocketVax is now initiating a Seed B financing round aimed at raising an additional CHF 5–10 million to support Phase 1 clinical trials expected to begin in Switzerland in the second quarter of 2022.startupticker.chEncouraging progress of COVID-19 solutions from SwitzerlandSwiss companies announced progress on COVID-19 vaccines and treatments, including RocketVax receiving CHF 1 million for preclinical work and ACM Biosciences an Innosuisse grant. The FDA granted EUA for sotrovimab and Fast Track for ensovibep, while Polyphor and Altamira Medica reported positive preclinical and clinical trial results.PR NewswireSwiss Rockets AG anuncia la fundación de ROCKETVAX para el desarrollo de una vacuna de última generación contra el SARS-CoV-2Swiss Rockets AG announced the founding of RocketVax AG, a Basel-based subsidiary, to develop a next-generation SARS-CoV-2 vaccine using innovative Swiss DNA synthesis technology. The company acquired exclusive rights to develop the vaccine from ETH spin-off Gigabases Switzerland AG, which provides artificial viral genome design through high-performance computing and artificial intelligence. Swiss Rockets will act as an accelerator, providing additional funding, facilitating national and international financing rounds, and coordinating with experts from Swiss universities including the University of Basel and ETH Zürich.PR NewswireSwiss Rockets AG anuncia la fundación de ROCKETVAX para el desarrollo de una vacuna de última generación contra el SARS-CoV-2Swiss Rockets AG announced the founding of RocketVax AG, a Basel-based subsidiary, to develop a next-generation SARS-CoV-2 vaccine using innovative Swiss DNA synthesis technology. The new vaccine will be a complete but non-replicating SARS-CoV-2 virus that presents all essential protein components to the human immune system, distinguishing it from first-generation vaccines that only use single coronavirus proteins. Swiss Rockets acquired exclusive rights from ETH spin-off Gigabases Switzerland AG and is working with experts from various Swiss universities and research institutions, with the company providing infrastructure through cooperation with the canton of Basel-Stadt and the University of Basel.